Clinicopathological Correlation of Glioma Patients with respect to Immunohistochemistry Markers: A Prospective Study of 115 Patients in a Tertiary Care Hospital in North India.

ABSTRACT:

Background

With the incorporation of molecular subtyping in glioma patients in 2016 WHO classification, there is a need to understand the immunohistochemistry (IHC) marker expression in various glioma patients and to clinically correlate with various subgroups.

Objective

Aim of the study was to assess IHC marker expression profile in glioma patients and to clinically correlate them in various subgroups.

Materials and methods

The prospective study included 115 glioma patients. IHC markers (isocitrate dehydrogenase [IDH] 1, ATRX, P53, Ki-67 antibody) were done in all patients. Patients received treatment as per the grade of tumor. The patients were followed in 3 monthly intervals, for a period of 12 months. SPSS software version 20.0 was used for statistical analysis. T

SUBMITTER: Dahuja G 

PROVIDER: S-EPMC8751513 | biostudies-literature | 2021 Oct-Dec

REPOSITORIES: biostudies-literature